17,130 Shares in Guardant Health, Inc. $GH Bought by WINTON GROUP Ltd

WINTON GROUP Ltd bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 17,130 shares of the company’s stock, valued at approximately $2,570,000.

Other hedge funds have also recently bought and sold shares of the company. Allworth Financial LP increased its holdings in shares of Guardant Health by 12.4% during the 2nd quarter. Allworth Financial LP now owns 1,072 shares of the company’s stock worth $161,000 after purchasing an additional 118 shares during the period. GAMMA Investing LLC lifted its stake in shares of Guardant Health by 14.5% in the second quarter. GAMMA Investing LLC now owns 965 shares of the company’s stock valued at $145,000 after buying an additional 122 shares during the period. First Pacific Financial lifted its stake in shares of Guardant Health by 33.1% in the first quarter. First Pacific Financial now owns 559 shares of the company’s stock valued at $52,000 after buying an additional 139 shares during the period. ABS Investment Management LLC acquired a new stake in Guardant Health during the second quarter worth about $345,069,000. Finally, Xponance LLC increased its stake in Guardant Health by 2.1% during the fourth quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after acquiring an additional 199 shares during the period. 92.60% of the stock is owned by institutional investors.

Insider Buying and Selling

In related news, CEO Amirali Talasaz sold 143,028 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $151.54, for a total transaction of $21,674,463.12. Following the completion of the sale, the chief executive officer directly owned 1,881,336 shares of the company’s stock, valued at $285,097,657.44. This trade represents a 7.07% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Musa Tariq sold 1,951 shares of the business’s stock in a transaction on Monday, June 22nd. The stock was sold at an average price of $131.16, for a total value of $255,893.16. Following the completion of the transaction, the director directly owned 11,048 shares in the company, valued at approximately $1,449,055.68. This represents a 15.01% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 427,024 shares of company stock valued at $67,113,285 in the last ninety days. 5.60% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Piper Sandler upped their target price on Guardant Health from $135.00 to $193.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Citigroup boosted their price target on shares of Guardant Health from $150.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Barclays increased their price objective on shares of Guardant Health from $150.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Wolfe Research started coverage on shares of Guardant Health in a report on Tuesday, June 2nd. They set an “outperform” rating and a $150.00 price objective for the company. Finally, Rothschild & Co Redburn started coverage on shares of Guardant Health in a research note on Tuesday. They issued a “buy” rating and a $203.00 target price on the stock. One research analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Guardant Health presently has a consensus rating of “Moderate Buy” and an average price target of $188.12.

Guardant Health Stock Performance

GH opened at $157.38 on Friday. The firm has a market cap of $21.12 billion, a price-to-earnings ratio of -45.09 and a beta of 1.57. The firm’s 50-day simple moving average is $159.72 and its 200-day simple moving average is $124.64. Guardant Health, Inc. has a twelve month low of $53.40 and a twelve month high of $176.58.

Guardant Health (NASDAQ:GH) last announced its quarterly earnings results on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.34. The firm had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. The company’s revenue for the quarter was up 44.3% on a year-over-year basis. During the same period in the prior year, the business earned ($0.44) earnings per share. As a group, sell-side analysts anticipate that Guardant Health, Inc. will post -2.98 EPS for the current fiscal year.

Guardant Health Company Profile

Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based diagnostic tests designed to help detect cancer, guide treatment decisions and monitor patients over time. Its liquid biopsy technologies analyze tumor-related signals in blood, reducing the need for tissue biopsies in certain clinical and research settings.

The company’s products include Guardant360 tests, which profile advanced cancers and can help identify potentially actionable genomic alterations; Guardant Reveal, which is used to assess residual disease and recurrence risk; and Guardant Shield, a blood-based screening test for colorectal cancer.